Akichika Ozeki

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

Takashi Kadowaki, Rina Chin, Akichika Ozeki et al. · The Lancet Diabetes & Endocrinology · 2022 · 115 citations

Diabetes Management, Diabetes, Pharmacology +6

Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial

Fumihiko Sakai, Akichika Ozeki, Vladimir Skljarevski · Cephalalgia Reports · 2020 · 41 citations · Full text

Cluster Headache, Subcutaneous Injections, Migraine Headache +11

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia

Takaki Yoshikawa, Kei Muro, Kohei Shitara et al. · JAMA Network Open · 2019 · 38 citations · Full text

A long-term open-label safety study of galcanezumab in Japanese patients with migraine

Koichi Hirata, Takao Takeshima, Fumihiko Sakai et al. · Expert Opinion on Drug Safety · 2021 · 29 citations · Full text

A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial

Masanori Emoto, Yasuo Terauchi, Akichika Ozeki et al. · Endocrine Journal · 2015 · 28 citations · Full text

Pharmacotherapy, Molecular Pharmacology, Diabetes Epidemiology +16